Veracyte wins Medicare coverage for Prosigna breast cancer test
Veracyte has secured Medicare reimbursement for its Prosigna Breast Risk of Recurrence test through Palmetto GBA's MolDX programme, marking a significant commercial milestone for the South San Francisco-based diagnostics company following the test's US launch in June 2026.
Coverage took effect on 19 August 2026 and applies to postmenopausal women with early-stage, oestrogen receptor-positive breast cancer classified as stage I or II with zero to three positive lymph nodes. The decision follows a Technical Assessment submission under MolDX, the programme through which the Centers for Medicare and Medicaid Services evaluates molecular diagnostics for local coverage determinations.
The test and the clinical evidence
Prosigna analyses a tumour's molecular biology alongside standard clinical and pathological factors to generate a 10-year recurrence risk score. Its primary utility is in helping oncologists and patients weigh the benefit of adjuvant chemotherapy against its toxicity burden.
The reimbursement decision comes backed by prospective randomised data. The independent OPTIMA phase III trial, led by University College London and presented at ASCO 2026, found that Prosigna-guided decision-making could spare chemotherapy in more than two-thirds of patients classified as clinically high-risk, without compromising outcomes. That trial, published in the Journal of Clinical Oncology, strengthens the evidentiary case that clinical benefit, not laboratory performance alone, underpins the coverage decision.
Chief executive Marc Stapley described the Medicare determination as "a key step in establishing broad coverage for Prosigna," and said the milestone would help oncologists make confident treatment choices for their patients.
Market context and competitive landscape
Genomic risk-stratification tests for early-stage breast cancer represent a well-established and competitive diagnostic category. Exact Sciences' Oncotype DX has long held the dominant commercial position in the US market and benefits from the landmark TAILORx trial evidence, while Biotheranostics' Breast Cancer Index addresses a different clinical question around extended endocrine therapy. Prosigna, which was developed from the PAM50 gene signature originally validated at the University of North Carolina, has historically had stronger uptake outside the United States, particularly in Europe. Securing MolDX coverage removes a major structural barrier to US market penetration, and Veracyte will now need to demonstrate commercial traction against entrenched competitors.
The broader molecular diagnostics reimbursement environment has grown more demanding in recent years. The CMS finalised the Medicare Clinical Diagnostic Laboratory Test (CDLT) payment schedule review in 2025, applying downward pricing pressure across a range of genomic assays, and multiple laboratory-developed tests are awaiting fresh coverage determinations. Veracyte's success with MolDX here is relevant read-across for other companies pursuing similar pathways.
Veracyte's existing diagnostics portfolio, which includes the Afirma thyroid, Decipher bladder and prostate, and TrueMRD tests, gives the company a diversified revenue base as Prosigna builds its US payer network. The company offers financial assistance through its Veracyte Access Programme for uninsured and underinsured patients pending broader commercial coverage negotiations.